BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 10640735)

  • 1. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.
    Ito D; Ogasawara K; Matsushita K; Morohashi T; Namba K; Matsuki N; Kitaichi N; Inuyama Y; Hosokawa M; Nakayama E; Iwabuchi K; Onoé K
    Immunobiology; 2000 Apr; 201(5):527-40. PubMed ID: 10834311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen.
    Hernández J; Ko A; Sherman LA
    J Immunol; 2001 Mar; 166(6):3908-14. PubMed ID: 11238635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation.
    Zhan Y; Corbett AJ; Brady JL; Sutherland RM; Lew AM
    J Immunol; 2000 Oct; 165(7):3612-9. PubMed ID: 11034363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
    Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M
    J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
    Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
    J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
    Krishnan L; Sad S; Patel GB; Sprott GD
    J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
    Kelleher M; Beverley PC
    J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways.
    DiPaolo RJ; Unanue ER
    J Immunol; 2002 Sep; 169(6):2832-6. PubMed ID: 12218093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.
    Williams MA; Trambley J; Ha J; Adams AB; Durham MM; Rees P; Cowan SR; Pearson TC; Larsen CP
    J Immunol; 2000 Dec; 165(12):6849-57. PubMed ID: 11120808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL.
    Prilliman KR; Lemmens EE; Palioungas G; Wolfe TG; Allison JP; Sharpe AH; Schoenberger SP
    J Immunol; 2002 Oct; 169(8):4094-7. PubMed ID: 12370335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.
    Van Gool SW; de Boer M; Ceuppens JL
    J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
    McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F
    J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple costimulatory modalities enhance CTL avidity.
    Hodge JW; Chakraborty M; Kudo-Saito C; Garnett CT; Schlom J
    J Immunol; 2005 May; 174(10):5994-6004. PubMed ID: 15879092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells.
    Eck SC; Turka LA
    Cancer Immunol Immunother; 1999 Sep; 48(6):336-41. PubMed ID: 10473809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
    Lu J; Higashimoto Y; Appella E; Celis E
    J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.